HOME >> MEDICINE >> NEWS
Acrux and Oreganon further expand their collaboration

Drug delivery company Acrux (ASX: ACR), announced today that it has signed a further agreement with Organon, the human healthcare business unit of Akzo Nobel, expanding the two parties' collaboration. This follows the recently announced deal under which Organon and Acrux will develop and commercialise contraceptives, delivered through the skin using Acrux's unique spray technology.

Under the new agreement, Organon has licensed Acrux's technology for delivery of a non-hormone, proprietary Organon drug, for a substantial global women's health market.

"The expansion of our important relationship with Organon, one of the leading innovators in women's health, confirms that our unique spray technology has even broader potential" said Acrux CEO Richard Treagus.

"This adds a new, non-hormone drug to our pipeline and demonstrates the potential to use the technology to deliver drugs owned by our partners", he added.

Organon executive vice president, Research and Development, David Nicholson commented "The Acrux technology is an appealing method of delivering medication, with the potential to extend the choices available for women to fit their needs and lifestyle."

Acrux will be responsible for developing formulations of the undisclosed compound and upon successful completion; Organon will undertake and fund all clinical trials, regulatory submissions, manufacturing and commercialization efforts.

Acrux may receive payments totalling US$12 million as development and regulatory milestones are achieved.

Acrux will also earn royalties on worldwide sales of the product.


'"/>

Contact: Richard Treagus
richard.treagus@acrux.com.au
61-383-790-100
Research Australia
6-Mar-2007


Page: 1

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. Acrux patent portfolio advances in USA
4. Acrux acquires rights to commercialise worlds first contraceptive spray
5. Four new us patents granted to Acrux for transdermal drug delivery
6. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
7. Stomach cancer rate set to fall further 25 percent over next decade
8. High tech help to prevent further heart disease
9. Altered activity in receptor pair points to further complexity in schizophrenia pathology
10. Mount Sinai and YAI/NIPD Network join forces to further quality of care for people with autism
11. Data further examines Seroquel (quetiapine fumarate) treatment for bipolar depression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor ... leant his presence to an educational purpose as the host of the “Informed” series. ... cancer. In a recent episode, the series focuses on thyroid cancer. , Although thyroid ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to meet talent shortages ... outdated healthcare executive resume. , “If you’re a healthcare executive open to new opportunities ... if it’s as ready as you are for a new job search. I’ve heard ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... 2017 Halo Labs announces the launch of ... system called the Horizon at PEGS 2017 in ... system analyzes sub visible particulate matter in biopharmaceutical samples ... as early as candidate selection and pre-formulation. ... research organization Elion Labs for system validation. ...
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology:
Cached News: